Targeting the Bcl-2 family of proteins in Hodgkin lymphoma: in vitro cytotoxicity, target modulation and drug combination studies of the Bcl-2 homology 3 mimetic ABT-737

References

• Nishikori M, Uchiyama T. Molecular pathogenesis of Hodgkin lymphoma. Int J Hematol 2006; 83: 398–403
   PubMed Web of Science ®Google Scholar
• Felberbaum R S. The molecular mechanisms of classic Hodgkin's lymphoma. Yale J Biol Med 2005; 78: 203–210
   PubMedGoogle Scholar
• Jost P J, Ruland J. Aberrant NF-κB signaling in lymphoma: mechanisms, consequences, and therapeutic implications. Blood 2007; 109: 2700–2707
   PubMed Web of Science ®Google Scholar
• Cochet O, Frelin C, Peyron J F, Imbert V. Constitutive activation of STAT proteins in the HDLM-2 and L540 Hodgkin lymphoma-derived cell lines supports cell survival. Cell Signal 2006; 18: 449–455
   PubMed Web of Science ®Google Scholar
• Tzankov A, Dirnhofer S. Pathobiology of classical Hodgkin lymphoma. Pathobiology 2006; 73: 107–125
   PubMed Web of Science ®Google Scholar
• Bai M, Papoudou-Bai A, Horianopoulos N, Grepi C, Agnantis N J, Kanavaros P. Expression of bcl2 family proteins and active caspase 3 in classical Hodgkin's lymphomas. Hum Pathol 2007; 38: 103–113
   PubMed Web of Science ®Google Scholar
• Aktaş S, Kargi A, Olgun N, Diniz G, Erbay A, Vergin C. Prognostic significance of cell proliferation and apoptosis-regulating proteins in Epstein–Barr virus positive and negative pediatric Hodgkin lymphoma. Lymphat Res Biol 2007; 5: 175–182
   PubMedGoogle Scholar
• Spector N, Milito C B, Biasoli I, Luiz R R, Pulcheri W, Morais J C. The prognostic value of the expression of Bcl-2, p53 and LMP-1 in patients with Hodgkin's lymphoma. Leuk Lymphoma 2005; 46: 1301–1306
   PubMed Web of Science ®Google Scholar
• Sup S J, Alemañy C A, Pohlman B, et al. Expression of bcl-2 in classical Hodgkin's lymphoma: an independent predictor of poor outcome. J Clin Oncol 2005; 23: 3773–3779
   PubMed Web of Science ®Google Scholar
• Kim L H, Nadarajah V S, Peh S C, Poppema S. Expression of Bcl-2 family members and presence of Epstein–Barr virus in the regulation of cell growth and death in classical Hodgkin's lymphoma. Histopathology 2004; 44: 257–267
   PubMed Web of Science ®Google Scholar
• Rassidakis G Z, Medeiros L J, Vassilakopoulos T P, et al. BCL-2 expression in Hodgkin and Reed-Sternberg cells of classical Hodgkin disease predicts a poorer prognosis in patients treated with ABVD or equivalent regimens. Blood 2002; 100: 3935–3941
   PubMed Web of Science ®Google Scholar
• van Spronsen D J, Peh S C, Vrints L W, van Imhoff G W, Poppema S. Clinical drug-resistant nodular sclerosing Hodgkin's lymphoma is associated with decreased bcl-2 expression in the surrounding lymphocytes and with increased bcl-2 expression in the Reed-Sternberg cells. Histopathology 2000; 37: 420–426
   PubMed Web of Science ®Google Scholar
• Kanavaros P, Stefanaki K, Vlachonikolis J, et al. Expression of p53, p21/waf1, bcl-2, bax, Rb and Ki67 proteins in Hodgkin's lymphomas. Histol Histopathol 2000; 15: 445–453
   PubMed Web of Science ®Google Scholar
• Rassidakis G Z, Medeiros L J, Vassilakopoulos T P, et al. BCL-2 expression in Hodgkin and Reed-Sternberg cells of classical Hodgkin disease predicts a poorer prognosis in patients treated with ABVD or equivalent regimens. Blood 2002; 100: 3935–3941
   PubMed Web of Science ®Google Scholar
• Chabay P, Pesce P, De Matteo E, Lombardi M G, Rey G, Preciado M V. No Influence of bcl-2, p53, and p21waf1 protein expression on the outcome of pediatric Hodgkin lymphomas. J Pediatr Hematol Oncol 2006; 28: 552–558
   PubMed Web of Science ®Google Scholar
• Amini R M, Berglund M, Rosenquist R, et al. A novel B-cell line (U-2932) established from a patient with diffuse large B-cell lymphoma following Hodgkin lymphoma. Leuk Lymphoma 2002; 43: 2179–2189
   PubMed Web of Science ®Google Scholar
• Zheng B, Fiumara P, Li Y V, et al. MEK/ERK pathway is aberrantly active in Hodgkin disease: a signaling pathway shared by CD30, CD40, and RANK that regulates cell proliferation and survival. Blood 2003; 102: 1019–1027
   PubMed Web of Science ®Google Scholar
• Zhang L, Ming L, Yu J. BH3 mimetics to improve cancer therapy; mechanisms and examples. Drug Resist Update 2007; 10: 207–217
   PubMed Web of Science ®Google Scholar
• Adams J M, Cory S. Bcl-2-regulated apoptosis: mechanism and therapeutic potential. Curr Opin Immunol 2007; 19: 488–496
   PubMed Web of Science ®Google Scholar
• Letai A. BH3 domains as BCL-2 inhibitors: prototype cancer therapeutics. Expert Opin Biol Ther 2003; 3: 293–304
   PubMed Web of Science ®Google Scholar
• Stauffer S R. Small molecule inhibition of the Bcl-X(L)-BH3 protein–protein interaction: proof-of-concept of an in vivo chemopotentiator ABT-737. Curr Top Med Chem 2007; 7: 961–965
   PubMed Web of Science ®Google Scholar
• Del Gaizo Moore V, Schlis K D, Sallan S E, Armstrong S A, Letai A. BCL-2 dependence and ABT-737 sensitivity in acute lymphoblastic leukemia. Blood 2008; 111: 2300–2309
   PubMed Web of Science ®Google Scholar
• Lock R, Carol H, Houghton P J, et al. Initial testing (stage 1) of the BH3 mimetic ABT-263 by the pediatric preclinical testing program. Pediatr Blood Cancer 2007; 50: 1181–1189
   Web of Science ®Google Scholar
• Deng J, Carlson N, Takeyama K, Dal Cin P, Shipp M, Letai A. BH3 profiling identifies three distinct classes of apoptotic blocks to predict response to ABT-737 and conventional chemotherapeutic agents. Cancer Cell 2007; 12: 171–185
   PubMed Web of Science ®Google Scholar
• Kuroda J, Puthalakath H, Cragg M S, et al. Bim and Bad mediate imatinib-induced killing of Bcr/Abl + leukemic cells, and resistance due to their loss is overcome by a BH3 mimetic. Proc Natl Acad Sci USA 2006; 103: 14907–14912
   PubMed Web of Science ®Google Scholar
• Kline M P, Rajkumar S V, Timm M M, et al. ABT-737, an inhibitor of Bcl-2 family proteins, is a potent inducer of apoptosis in multiple myeloma cells. Leukemia 2007; 21: 1549–1560
   PubMed Web of Science ®Google Scholar
• Chauhan D, Velankar M, Brahmandam M, et al. A novel Bcl-2/Bcl-X(L)/Bcl-w inhibitor ABT-737 as therapy in multiple myeloma. Oncogene 2007; 26: 2374–2380
   PubMed Web of Science ®Google Scholar
• Trudel S, Stewart A K, Li Z, et al. The Bcl-2 family protein inhibitor, ABT-737, has substantial antimyeloma activity and shows synergistic effect with dexamethasone and melphalan. Clin Cancer Res 2007; 13(2 Part 1)621–629
   PubMed Web of Science ®Google Scholar
• Shoemaker A R, Oleksijew A, Bauch J, et al. A small-molecule inhibitor of Bcl-XL potentiates the activity of cytotoxic drugs in vitro and in vivo. Cancer Res 2006; 66: 8731–8739
   PubMed Web of Science ®Google Scholar
• Witham J, Valenti M R, De-Haven-Brandon A K, et al. The Bcl-2/Bcl-XL family inhibitor ABT-737 sensitizes ovarian cancer cells to carboplatin. Clin Cancer Res 2007; 13: 7191–7198
   PubMed Web of Science ®Google Scholar
• Kuroda J, Kimura S, Strasser A, et al. Apoptosis-based dual molecular targeting by INNO-406, a second-generation Bcr-Abl inhibitor, and ABT-737, an inhibitor of antiapoptotic Bcl-2 proteins, against Bcr-Abl-positive leukemia. Cell Death Differ 2007; 14: 1667–1677
   PubMed Web of Science ®Google Scholar
• Cragg M S, Kuroda J, Puthalakath H, Huang D C, Strasser A. Gefitinib-induced killing of NSCLC cell lines expressing mutant EGFR requires BIM and can be enhanced by BH3 mimetics. PLoS Med 2007; 4: 1681–1689
   PubMed Web of Science ®Google Scholar
• Kang M H, Kang Y H, Szymanska B, et al. Activity of vincristine, L-ASP, and dexamethasone against acute lymphoblastic leukemia is enhanced by the BH3-mimetic ABT-737 in vitro and in vivo. Blood 2007; 110: 2057–2066
   PubMed Web of Science ®Google Scholar
• Narendran A, Ganjavi H, Morson N, et al. Mutant p53 in bone marrow stromal cells increases VEGF expression and supports leukemia cell growth. Exp Hematol 2003; 31: 693–701
   PubMed Web of Science ®Google Scholar
• Hawkins L M, Jayanthan A A, Narendran A. Effects of 17-allylamino-17-demethoxygeldanamycin (17-AAG) on pediatric acute lymphoblastic leukemia (ALL) with respect to Bcr-Abl status and imatinib mesylate sensitivity. Pediatr Res 2005; 57: 430–437
   PubMed Web of Science ®Google Scholar
• Ahmed S A, Gogal R M, Jr, Walsh J E. A new rapid and simple non-radioactive assay to monitor and determine the proliferation of lymphocytes: an alternative to 3H.thymidine incorporation assay. J Immunol Methods 1994; 170: 211–224
   PubMed Web of Science ®Google Scholar
• Kwack K, Lynch R G. A new non-radioactive method for IL-2 bioassay. Mol Cells 2000; 10: 575–578
   PubMed Web of Science ®Google Scholar
• Hudson L, Hay F C. The lymphocyte: its role and function, 2nd edn. Practical immunology. Blackwell Scientific Publications, Oxford 1980; 29–32
   Google Scholar
• Higurashi H, Arai M, Watanabe A, et al. Gene expression profiling of polymorphonuclear leukocytes treated with the culture filtrate of Aspergillus fumigatus and gliotoxin. Microbiol Immunol 2007; 51: 407–419
   PubMed Web of Science ®Google Scholar
• Teruya T, Konishi T, Uechi S, Tamaki H, Tako M. Anti-proliferative activity of oversulfated fucoidan from commercially cultured Cladosiphon okamuranus TOKIDA in U937 cells. Int J Biol Macromol 2007; 41: 221–226
   PubMed Web of Science ®Google Scholar
• Zhao L, Wientjes G, Au J. Evaluation of combination chemotherapy: integration of nonlinear regression, curve shift, Isobologram and combination index analyses. Clin Cancer Res 2004; 10: 7994–8004
   PubMed Web of Science ®Google Scholar
• Oltersdorf T, Elmore S W, Shoemaker A R, et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 2005; 435: 677–681
   PubMed Web of Science ®Google Scholar
• Konopleva M, Contractor R, Tsao T, et al. Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia. Cancer Cell 2006; 10: 375–388
   PubMed Web of Science ®Google Scholar
• Zhang W, Konopleva M, Ruvolo V R, et al. Sorafenib induces apoptosis of AML cells via Bim-mediated activation of the intrinsic apoptotic pathway. Leukemia 2008; 22: 808–818
   PubMed Web of Science ®Google Scholar
• Yu C, Bruzek L M, Meng X W, et al. The role of Mcl-1 downregulation in the proapoptotic activity of the multikinase inhibitor BAY 43-9006. Oncogene 2005; 24: 6861–6869
   PubMed Web of Science ®Google Scholar
• van Delft M F, Wei A H, Mason K D, et al. The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized. Cancer Cell 2006; 10: 389–399
   PubMed Web of Science ®Google Scholar
• Paoluzzi L, Gonen M, Bhagat G, et al. The BH3-only mimetic ABT-737 synergizes the antineoplastic activity of proteasome inhibitors in lymphoid malignancies. Blood 2008; 112: 2906–2916
   PubMed Web of Science ®Google Scholar
• Duus J, Bahar H I, Venkataraman G, et al. Analysis of expression of heat shock protein-90 (HSP90) and the effects of HSP90 inhibitor (17-AAG) in multiple myeloma. Leuk Lymphoma 2006; 47: 1369–1378
   PubMed Web of Science ®Google Scholar
• Kutuk O, Letai A. Alteration of the mitochondrial apoptotic pathway is key to acquired paclitaxel resistance and can be reversed by ABT-737. Cancer Res 2008; 68: 7985–7994
   PubMed Web of Science ®Google Scholar
• Chen J, Fiskus W, Eaton K, et al. Co-treatment with BCL-2 antagonist sensitizes cutaneous T cell lymphoma to lethal action of HDAC7-Nur77 based mechanism. Blood, 2008(Dec) Epub ahead of print
   Google Scholar
• Bargou R C, Leng C, Krappmann D, et al. High-level nuclear NF-κ B and Oct-2 is a common feature of cultured Hodgkin/Reed-Sternberg cells. Blood 1996; 87: 4340–4347
   PubMed Web of Science ®Google Scholar
• Bargou R C, Emmerich F, Krappmann D, et al. Constitutive nuclear factor-κB-RelA activation is required for proliferation and survival of Hodgkin's disease tumor cells. J Clin Invest 1997; 100: 2961–2969
   PubMed Web of Science ®Google Scholar
• Bernal-Mizrachi L, Lovly C M, Ratner L. The role of NF-{κ} B-1 and NF-{κ}B-2-mediated resistance to apoptosis in lymphomas. Proc Natl Acad Sci USA 2006; 103: 9220–9225
   PubMed Web of Science ®Google Scholar
• García J F, Camacho F I, Morente M, et al. Hodgkin and Reed-Sternberg cells harbor alterations in the major tumor suppressor pathways and cell-cycle checkpoints: analyses using tissue microarrays. Blood 2003; 101: 681–689
   PubMed Web of Science ®Google Scholar